On 16 January 2014, orphan designation (EU/3/13/1232) was granted by the European Commission to ORS Oxford Ltd, United Kingdom, for allantoin for the treatment of epidermolysis bullosa.
The sponsorship was transferred as follows:
• to Scioderm Limited, Ireland, in October 2014;
• to Amicus Therapeutics UK Ltd, United Kingdom, February 2016;
• and finally to Amicus Therapeutics Europe Limited, Ireland, in March 2019.
|Disease / condition||
Treatment of epidermolysis bullosa
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.